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Introduction
Macrophage activation syndrome (MAS) is a rare but
life threatening complication of infectious, neoplastic
and rheumatic diseases. Clinically, patients usually have
high fever, hepatosplenomegaly, lymphadenopathy and
neurologic symptoms. In laboratory results pathogno-
monic are pancytopenia, decline in the value of sedi-
mentation rate (ESR), increased levels of ferritin and
coagulation abnormalities.
Objectives
The aim of the study is to present the case of Macro-
phage Activation Syndrome in a Patient With Juvenile
Systemic Lupus Erythematosus.
Methods
The clinical course and results of the diagnostic tests
were analyzed on the basis of the patient ’s medical
history.
Results
16-year-old male patient 8 months prior to admission
presented fatigue, weakness, weight loss and facial
erythema with edema. On admission, the patient was
confused, he had trembling extremities, scanning speech
and a fever of 38,8 °C. Physical exam revealed muscle
atrophy, lymphadenopathy, oral ulcers, echymosses, pal-
mar erythema and malar rush. An infectious process was
ruled out with viral panel and bacterial cultures. The
blood count showed pancytopenia, increased ESR, AST
and ASP, hypocomplementemia, hypertriglyceridemia
and hyperferritinemia. Subsequently the patient pre-
sented antinuclear antibody in titer 1:20480 with a
speckled pattern, positive anti-Sm and positive anti-
ribosomal P protein antibodies. Bone marrow biopsy
showed no changes typical for MAS. With this data the
diagnosis of SLE was reached and treatment with pulses
of glukocorticoids and an IVIG was started. During the
next three days of hospitalization laboratory results were
constantly getting worse despite the treatment and new
clinical symptoms occurred (neurologic symptoms and
bleeding from mucous membranes). Based on clinical
manifestation and results of laboratory tests the patient
was diagnosed with Macrophage Activation Syndrome
secondary to SLE and the treatment with cyclosporine
was added. Despite the clinical and laboratory tests
improvement in the next five days the patient had a sei-
zure attack followed by a cardiac arrest and after success-
ful reanimation he was transferred to a intensive care
unit. After two weeks the patient was again admitted to
the clinic, he was conscious and respiratory stable
although there was no logical contact, no reflexes in
upper limbs, weak reflexes in lower limbs, profound mus-
cle atrophy and hydrocephalus. Blood cell counts, mar-
kers of inflammation and other abnormalities in
biochemical returned to normal.
Conclusion
The diagnosis of MAS secondary to SLE is difficult due
to common characteristics such as fever, pancytopenia,
lymphadenopathy, neurological symptoms and skin
manifestations. Careful assessment of laboratory results
especially pancytopenia, hyperferritinemia and hypofibri-
nogenemia is crucial and leads to a quick and accurate
diagnosis which is very important as MAS is considered to
be a severe complication which puts patient’s life at risk.
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